Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE MAGNESIUM versus EZALLOR SPRINKLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE MAGNESIUM versus EZALLOR SPRINKLE.
ESOMEPRAZOLE MAGNESIUM vs EZALLOR SPRINKLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase at the secretory surface of gastric parietal cells.
EZALLOR SPRINKLE (rosuvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It increases hepatic LDL receptor expression, enhancing LDL clearance from plasma and reducing VLDL synthesis.
20-40 mg orally once daily; for erosive esophagitis, 40 mg once daily for 4-8 weeks. IV: 20-40 mg once daily over 10-30 minutes.
40 mg orally once daily at bedtime; initial dose may be 20 mg. Dose range: 20-80 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours in healthy individuals, but may be prolonged to 2–3 hours in poor metabolizers (CYP2C19) or patients with hepatic impairment. The effect on gastric acid secretion persists for 24 hours due to irreversible binding to proton pumps.
Terminal elimination half-life is approximately 19 hours (range 13-20 hours) in healthy volunteers; half-life is prolonged in patients with hepatic impairment and severe renal impairment, necessitating dose adjustments.
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (about 20%) eliminated in feces via biliary excretion. Less than 1% is excreted unchanged in urine.
Renal excretion accounts for approximately 88% of the administered dose (56% as unchanged rosuvastatin and 32% as metabolites); fecal excretion accounts for approximately 12%.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor